Overview
Orlando 2004 Component Meeting and dbMHC-HCT Launch
HCT Joint Reports (pre-publication)
Questionnaire
HSCT Newsletter
Issue 2
Issue 1
Meeting Minutes
Keystone, Jan 03
San Francisco, Oct 01
Keystone, Feb 01
Orlando, Oct 00
Paris, July 99
Miami, Dec 98
Vancouver, Oct 98
Joint Projects
HCT-Cytokine Gene Polymorphisms Project (PDF)
HCT-KIR Genes Project (PDF)
Send us your data!
Combined HCT-KIR-CGP Data Entry Form
Data entry instructions
KIR Phase II Reference Panel Data Submission Form
KIR Typing Protocol
Phase I Reference Panel: Consensus KIR Gene Assignment
HCT Summary and FAQ
Microsatellite protocol (PDF)
Effie Petersdorf, Chair
Background
The overall goal of the Hematopoietic Cell Transplantation Component is to develop resources for scientific inquiry into the genomics of transplantation. The working group will first develop an international cell and DNA repository of donor-recipient transplant pairs that are not already available through existing repositories. The working group will not duplicate cells and DNA if these materials are available in other repositories. The working group will also identify and collect samples that have, up until now, been missing from existing repositories. The working group has defined a minimum requisite of 2 mg of genomic DNA or 2 vials of 5 X 106 PBL on each donor and patient. For laboratories not wishing to transform cell lines, the IHWC will transform cell lines at the Fred Hutchinson Cancer Research Center (FHCRC). For all transplants henceforth, the working group desires to save a minimum of 2 vials of 5 X 106 PBL and 2 mg of genomic DNA. The FHCRC will transform cell lines if the contributing laboratory does not have the facilities to do so.
The second specific aim of the component is to fully characterize each donor-recipient pair for alleles encoded at HLA-A, B, C, DRB, DQB1 and DPB1. This will be accomplished by collecting all HLA typing information available at the time of transplant, identification of samples requiring further allele-level typing, and use of SSOP and SBT standardized protocols developed by the Typing Technologu Component for completion of the typing. In the third aim of the study, the relevance of complete allele matching to clinical outcome will be evaluated. For the purposes of reducing heterogeneity in the study population and to decrease inter-observer variation in the definition of clinical endpoints, the working group will focus on the analysis of CML unrelated transplants with survival as the primary endpoint. Acute and chronic GVHD are the secondary endpoints of the study. Clinical data collection will use existing report forms from the NMDP and IBMTR. If clinical data is not submitted via the NMDP or IBMTR, the working group will identify those transplants and liaison directly with the transplant centers.
The fourth aim of the study will be to evaluate the clinical impact of disparity for microsatellites and for single nucleotide polymorphisms (SNPs). The overall objectives are to determine whether microsatellite markers, in defining a larger part of the MHC can provide new information on donor-recipient matching than is currently gained by typing each class I and II gene. The presence of disparity for microsatellite markers may indicate that the patient and donor have different extended haplotypes. The analysis of SNPs will represent the stepping stones for investigating the role of polymorphisms encoded outside the MHC in clinical transplantation.
Finally, the project will seek to define permissible mismatches. The specific mismatches to be analyzed will depend on the overall allele and haplotype frequencies encoded in the international set of data, but will likely enable examination of common alleles (for example, A2, B44 and DR4) as a minimum.
